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Abstract: Hyperinsulinemia could have a role in the growing incidence of esophageal
adenocarcinoma (EAC) and its pre-cancerous lesion, Barrett’s Esophagus, a possible consequence of
Gastro-Esophageal Reflux Disease. Obesity is known to mediate esophageal carcinogenesis through
different mechanisms including insulin-resistance leading to hyperinsulinemia, which may mediate
cancer progression via the insulin/insulin-like growth factor axis. We used the hyperinsulinemic
non-obese FVB/N (Friend leukemia virus B strain) MKR (muscle (M)-IGF1R-lysine (K)-arginine (R)
mouse model to evaluate the exclusive role of hyperinsulinemia in the pathogenesis of EAC related to
duodeno-esophageal reflux. FVB/N wild-type (WT) and MKR mice underwent jejunum-esophageal
anastomosis side—to end with the exclusion of the stomach. Thirty weeks after surgery, the esophagus
was processed for histological, immunological and insulin/Insulin-like growth factor 1 (IGF1) signal
transduction analyses. Most of the WT mice (63.1%) developed dysplasia, whereas most of the MKR
mice (74.3%) developed squamous cell and adenosquamous carcinomas, both expressing Human
Epidermal growth factor receptor 2 (HER2). Hyperinsulinemia significantly increased esophageal
cancer incidence in the presence of duodenal-reflux. Insulin receptor (IR) and IGF1 receptor (IGF1R)
were overexpressed in the hyperinsulinemic condition. IGF1R, through ERK1/2 mitogenic pattern
activation, seems to be involved in cancer onset. Hyperinsulinemia-induced IGF1R and HER2
up-regulation could also increase the possibility of forming of IGF1R/HER2 heterodimers to support
cell growth/proliferation/progression in esophageal carcinogenesis.
Keywords: hyperinsulinemia; duodenal reflux; esophageal cancer; MKR mouse model; insulin-like
growth factor 1 receptor; human epidermal growth factor receptor 2
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1. Introduction
Esophageal adenocarcinoma (EAC) is the most rapidly increasing form of cancer in some
populations [1]. Barrett’s mucosa is assumed to be a pre-cancerous lesion for EAC [2] and it is defined
as columnar epithelium, replacing esophageal squamous epithelium, initiated by reparative processes
in the setting of gastro-esophageal reflux disease (GERD). It is reported that not only gastric acid,
but also the duodenal basic content (bile acids in particular) play an important role in the generation
of columnar metaplasia [3]. Obesity has been previously identified as an important risk factor for EAC,
which is known to predispose patients to increased gastro-esophageal reflux, due to anatomic factors
such as increased abdominal and intraperitoneal adiposity, and hiatal hernia formation [4]. Obesity
is also known to mediate cancer progression through insulin-resistance, inflammation and oxidative
stress, and production of fat-associated hormones (adipokines). Obesity is associated with a number
of comorbidities, among them hypertension, hyperlipidemia, and diabetes mellitus [5]. Previous
reports have shown that diabetes increases the risk for several types of cancer and treatment with
the antidiabetic drug metformin may decrease this risk [6–9]. Moreover, hyperinsulinemia and
insulin resistance may mediate cancer progression via the insulin/insulin-like growth factor axis [8,10].
The specific mechanisms involved in this tumor-promoting activity are unclear. Furthermore, Human
Epidermal growth factor receptor 2 (HER2) signaling activation is known to have a pivotal role in
EAC carcinogenesis and disease progression. A relationship between insulin and HER2 signaling was
already demonstrated for breast cancer [11–13] and could also be hypothesized in this context.
The aim of this study is to evaluate the exclusive role of hyperinsulinemia in the pathogenesis
of EAC related to chronic duodeno-esophageal reflux in a pre-diabetes context and in the absence of
obesity as confounding factor associated with cancer risk. To this purpose we used an animal model
(MKR mouse) that has already been largely used to demonstrate the specific role of hyperinsulinemia
in the development of other epithelial cancers such as breast cancer [8]. MKR mice were generated by
overexpressing a dominant-negative IGF1R specifically in skeletal muscle. The transgene encodes for
human IGF1R; it has a point mutation in the ATP-binding domain and is driven by the muscle creatine
kinase promoter, resulting in the inactivation of IR and IGF1R exclusively in skeletal muscle. Mice
develop a mild diabetic phenotype, which recapitulates the early stages of type 2 diabetes (pre-diabetes)
in humans. A mild dysglycemia, a marked hyperinsulinemia, and severe insulin resistance are the
major metabolic abnormalities detected in MKR female mice during their whole life; the severe
and uncompensated insulin resistance leads to diabetes development in old age MKR male mice.
Importantly, MKR mice are not obese; they have moderately reduced total body weight and body
adiposity compared with their control littermates [8].
2. Results
2.1. Macroscopic Findings in Operated Wild-Type and MKR Mice
Body weight was measured in all animals before surgery. According to previous work [8,14],
MKR mice had reduced total body weight (BW) compared to WT controls (Figure 1). Six animals died
in the post-operative period due to complications, such as malnutrition and/or breathing difficulties.
A total of 73 out of 79 (92.4%) mice completed the study. At the time of euthanasia, most of the operated
animals showed an enlargement of the esophageal cavity (especially the lower and middle parts),
increased thickness, and epithelium hyperkeratinization. Some animals showed cardiac hypertrophy
and splenomegaly (36.8% and 45.7% in WT and MKR groups, respectively; p = 0.482), possibly
secondary to anemia. As expected, in all animals the stomach was atrophied.
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Figure 1. Total body weight of 13-week-old wild-type (WT) and hyperinsulinemic (MKR) mice.
Data were expressed as Median (Q1; Q3). F: Female mice; M: Male mice. * Mann-Whitney U-test,
p = 3.8 × 10−4; ** Mann-Whitney U-test p = 2.0 × 10−6.
2.2. Histological Findings in Operated Wild-Type and MKR Mice
According to histological findings, animals were grouped into four main categories: (1) No
significant lesions with normal squamous epithelium; (2) Esophagitis; (3) Intraepithelial/noninvasive
neoplasia, formerly known as dysplasia; (4) Cancer. Non-ulcerative and ulcerative esophagitis
(category 2) was defined as sub-epithelial inflammatory infiltrate (mostly coexisting with intraepithelial
leukocytes) which is often coexistent with granulation tissue and hyperplastic-regenerative changes of
the surrounding epithelium. Intraepithelial/noninvasive neoplasia (category 3) was defined as the
presence of cytology atypia (of low or high grade) in the absence of an architectural disarrangement
or subepithelial invasion. Cancer (category 4) was defined as having invasive lesions consisting of
squamous epithelial cells or of solid nests of epithelia with focal glandular differentiation (Esophageal
Squamous Cell Carcinoma-ESCC). In some case, the neoplastic lesions featured both squamous and
glandular differentiation (Esophageal Adeno-Squamous Carcinoma-EASC).
Histological analyses revealed that 30 weeks after surgery, both WT and MKR mice, developed
esophageal neoplastic lesions.
In particular, most of the WT mice (n = 24 out of 38; 63.1%) developed esophageal dysplasia;
carcinoma was found in 31.6% of WT mice. However, most of the MKR mice (n = 26 out of 35; 74.3%)
developed esophageal cancer. Dysplasia was found in 11.4% of MKR mice that were subjected to
duodenal reflux (MKR vs. WT: OR 0.07, 95% CI 0.02–0.26, p < 0.0001 for dysplasia; OR 6.26, 95% CI
2.25–17.38, p = 0.0004 for carcinoma). In the remaining animals, histologic features of esophagitis,
including marked hyperplastic changes, such as increased thickness of the esophageal wall squamous
epithelium, and hyperkeratosis, were found (11.4% of MKR mice). No esophageal lesion was found in
5.3% and 2.9% of WT and MKR mice, respectively (Table 1).
Table 1. Incidence of esophageal pathological changes in wild-type (WT) and hyperinsulinemic (MKR)
mice with duodenal reflux. Data show the numbers of mice, with percentages in parentheses.
Group
Lesion
No Lesion Esophagitis Dysplasia Cancer
WT (n = 38) 2 (5.3) 0 (0.0) 24 (63.1) 12 (31.6)
MKR (n = 35) 1 (2.9) 4 (11.4) 4 (11.4) 26 (74.3)
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2.3. Lesion Histology and Gender Difference
Six animals out of 18 (33.3%) of WT males that underwent surgery developed cancer. Sixteen out
of 17 (94.4%) of MKR males that underwent surgery developed cancer (OR 32.00, 95% CI 3.39–302.23,
p = 0.002). Six animals out of 20 (30.0%) of WT females that underwent surgery developed cancer.
Ten out of 18 (55.5%) of MKR females that underwent surgery developed cancer (OR 2.92, 95% CI
0.77–11.07, p = 0.116). EASC development was significantly associated to male gender (OR 3.56, 95% CI
1.18–10.72, p = 0.024) (Table 2). No differences in cancer incidence were found between WT males and
WT females (OR 1.17, 95% CI 0.30–4.59, p = 0.825). On the contrary, cancer incidence on MKR males
was higher compared to MKR females (OR 12.80, 95% CI 1.38–118.32, p = 0.025).
All (100%) low-grade dysplastic lesions (LGD) affected esophageal squamous epithelium and
were predominantly found in WT females (Fisher’s exact test: p = 0.001 and p = 0.006 WT females
vs. WT males and vs. MKR females, respectively). High-grade dysplastic lesions (HGD) were found
in 21.0% of WT mice (75% males) and in 5.7% of MKR mice (100% females, no dysplastic lesions
were found in MKR males) and both esophageal squamous and glandular components were affected.
Table 2 summarizes histological analysis result for each animal group.
Table 2. Incidence of esophageal pathological changes in wild-type (WT) females and males and
hyperinsulinemic (MKR) females and males mice with duodenal reflux. Data show the numbers of
mice, with percentages in parentheses. Animals were divided by gender; dysplastic lesions were
divided based on the degree of histologic abnormality in LGD (Low-Grade Dysplasia) and HGD
(High-Grade Dysplasia); neoplastic lesions were divided by histotype in ESCC (Esophageal Squamous
Cell Carcinoma) and EASC (Esophageal Adeno-Squamous Carcinoma).
Group Gender No Lesion Esophagitis LGD HGD ESCC EASC
WT
(n = 38)
FEMALE
(n = 20) 1 (5.0) 0 (0.0) 11 (55.0) 2 (10.0) 4 (20.0) 2 (10.0)
MALE
(n = 18) 1 (5.5) 0 (0.0) 5 (27.8) 6 (33.4) 1 (5.5) 5 (27.8)
MKR
(n = 35)
FEMALE
(n = 18) 0 (0.0) 4 (22.2) 2 (11.1) 2 (11.1) 6 (33.4) 4 (22.2)
MALE
(n = 17) 1 (5.9) 0 (0.0) 0 (0.0) 0 (0.0) 7 (41.2) 9 (52.9)
2.4. Basal Serum Metabolic Parameters
To understand the metabolic status of the mice before surgery, fasting blood glucose and serum
insulin, C-peptide and leptin levels were measured at 13 weeks of age in non-operated animals.
After two hours of fasting, glucose levels were lower in female than in male mice, without any
significant difference between the four groups of mice (Kruskal-Wallis test result: p = 0.078). The Mann
Whitney U-test showed that the differences between female and male MKR mice were close to
statistical significance (p = 0.046) (Table S1, Supplementary Materials). Cuzick’s test for trend showed
that glucose level increased across the four ordered groups: WT females, WT males, MKR females,
MKR males (z = +2.04; p = 0.041). As expected, MKR mice showed marked hyperinsulinemia, 6–8-fold
higher than WT mice of the same gender. Furthermore, our data showed significantly higher serum
insulin in WT males compared to WT females (p = 1.6 × 10−3) (Table S1, Supplementary Materials).
Within MKR group, males had higher serum insulin than females, but the difference did not reach
statistical significance.
C-peptide levels, a more stable and accurate marker of endogenous insulin secretion, were higher
in MKR mice compared to their WT counterparts (Table S1, Supplementary Materials). Our data
showed no significant difference between males and females belonging to the same group. Cuzick
trend test showed significant increased levels of both serum insulin and C-peptide across the four
groups (z = +5.25, p < 1 × 10−4 and z = +4.03, p < 1 × 10−4, respectively).
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Leptin serum levels were significantly lower in MKR mice compared to age- and sex-matched
WT mice. No differences in leptin levels between females and males belonging to the same group were
found (Table S1, Supplementary Materials), although the differences between WT males and females
were close to statistical significance (p = 0.021). No differences in IL-6 serum levels among the four
groups were found (27.1 and 24.6 in WT females and males, respectively; 23.1 and 21.7 in MKR females
and males, respectively).
2.5. Basal Insulin Signaling in Mice Esophageal Tissue
To study the effect of hyperinsulinemia on esophageal cancer development, we evaluated insulin
signal transduction in esophageal tissue of non-operated animals at 13 weeks of age. It is known
that the biological effects of insulin are mediated by the structurally related Insulin receptor (IR)
and insulin-like growth factor receptor 1 (IGF1R). At physiological levels, insulin binds to the IR,
while IGF1 binds primarily to the IGF1R and IGF1R/IR hybrid receptors, and IGF2 binds to the
IGF1R and IR isoform A. IR and IGF1R transduce an intracellular signal primarily through the PI3K
pathway and the mitogen-activated protein kinase (MAPK) pathway [15]. We evaluated total protein
expression and phosphorylation level of IR and IGF1R from the distal esophageal segment of mice by
Luminex-xMAP® technology.
IR is a glycoprotein consisting of an extracellular α-subunit and a transmembrane β-subunit.
Insulin binding to the α-subunit results in the dimerization of the receptor, with the formation of
the α2β2 complex in the cell membrane, and the autophosphorylation of the β-subunit at tyrosine
residues [Y] 1158, 1162, and 1163, the first step in the activation of IR [16]. The level of IR (β subunit)
in esophageal tissue of MKR mice was significantly higher (about 2.7-fold) compared with WT
mice. We found no significant differences between males and females belonging to the same group
(Figure S1A, Supplementary Materials).
The expression level of IGF1R (total protein) in the same tissues was very high (about 10-fold) in
MKR esophageal tissue compared to WT expression. We found the highest expression in MKR males
although the differences with MKR females did not reach the statistical significance (p = 0.141).
Receptor phosphorylation level on tyrosine autophosphorylation sites was evaluated: both IR
[pYpY1162/1163] and IGF1R [pYpY1135/1136] expression levels ratio were lower in MKR compared to
WT mice of the same gender (Figure S1B, Supplementary Materials). No differences between females
and males belonging to the same group were found.
Both, expression and phosphorylation level of some proteins involved in insulin-mediated
intracellular signal transduction were analyzed. The activation of PI3K generates phosphatidylinositol
(3,4,5)-triphosphate (PIP3), a second messenger that activates 3-phosphoinositide-dependent protein
kinase 1 (PDK1) and PDK2, which mediate the effect of insulin on metabolism and cell survival.
PDK1 and PDK2, in turn, activate protein kinase B (Akt), by inducing phosphorylation at threonine
308 and serine 473 residues, respectively [16]. Our data showed a significant increase in Akt total
protein expression across the four groups (z = +2.06, p = 0.040) (Figure S1A). Similarly, Cuzick’s trend
test showed a progressive increase in Akt phosphorylation on serine 473 residue across the four groups
(z = +2.25, p = 0.024), with the highest expression in MKR males (Figure S1B).
After the beta-subunit autophosphorylation step, activated insulin receptor phosphorylates target
proteins such as Shc and the family of insulin receptor substrate (IRS) proteins on selective tyrosine
residues that serve as docking sites for downstream effector molecules. A lot of studies have focused
on Ser/Thr phosphorylation of the IRS proteins as a key negative-feedback control mechanism that
uncouples the IRS proteins from their upstream and downstream effectors, and terminates signal
transduction in response to insulin, under physiological conditions. Analogous mechanisms are
involved on the molecular pathophysiology of insulin resistance by activating serine/threonine IRS
kinases that phosphorylate the IRS proteins and inhibit their function. S6K1, a insulin-induced
serine/threonine kinase, negatively modulates insulin’s effects by phosphorylating IRS proteins on
serine residues [16,17]. We therefore analyzed IRS1 total and inhibited phosphorylated form on
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serine 307 residue expression in mice esophageal tissue. Figure S1A, showed that in MKR mice IRS1
total expression was up-regulated compared to WT mice. The differences between females groups
(MKR females vs. WT females, p = 0.004) was statistically significant while the difference between
males was close to statistical significance (p = 0.031). No evident differences in IRS1 levels were found
between males and females belonging to the same group. Data on the relative phosphorylation levels
of IRS1 showed a progressive increase across the four groups (z = +3.50, p = 5 × 10−4) with significant
differences also between MKR males and females (p = 0.004) (Figure S1B).
Total p70S6K and phosphorylated forms (threonine 421/serine 424) were also evaluated and no
difference was detected between the groups (Figure S1A,B).
Together with PI3K/Akt metabolic pathway, the second essential branch of the
insulin/IGF-1-signaling pathway is the mitogen-activated protein (MAP) kinase pathway which
mediates growth-promoting functions of insulin [16]. To study the state of the mitogenic signaling,
total ERK1/2 (Extracellular signal-Regulated Kinase) and phosphorylated ERK1/2 (threonine
185/tyrosine 187) expression were evaluated in the same esophageal tissue. As shown in Figure S1A a
significant increase of total ERK1/2 expression across the four groups was found (z = +2.63, p = 0.009).
The relative phosphorylated form was not significantly altered among the four groups (K-W, p = 0.165).
2.6. Serum Metabolic Parameters in Operated Mice
To evaluate possible changes that might be related to the onset of the disease, we measured the
metabolic parameters in the serum of animals subjected to anastomosis that developed dysplasia or
cancer and compared the values with the control groups. Our control group was represented by age
(43 weeks)- and sex-matched non-operated animals. We first analyzed the WT animals.
Analysis of serum from wild-type females showed no significant differences in metabolic
parameters in the multiple comparisons between non-operated animals and operated animals with
dysplastic and/or neoplastic lesions (Table 3). Cuzick’s test trend result showed that glucose levels
were increased along with disease progression (z = +2.35, p = 0.019).
Sera analysis in wild-type male mice showed a significant difference in leptin level in animals
subjected to surgery that developed dysplasia and cancer compared with non-operated controls
(Table 3). Cuzick’s test result confirmed that leptin levels decreased with disease progression (z = −2.94,
p = 0.003). As expected, IL-6 serum level increased along with disease progression (z = +2.01,
p = 0.044). No significant differences between 13 week- and 43 week-old wild-type animals were found.
Mann-Whitney U-test showed significantly lower serum insulin concentrations in non-operated WT
females compared to WT males at 43 weeks of age (p = 0.008) with no significant differences in glucose
level (p = 0.674).
As showed in Table 4, the Kruskal-Wallis test suggested no significant differences in serum
metabolic parameters between non-operated and operated MKR females. All metabolic serum
parameters were slightly higher in non-operated MKR females at 43 weeks of age compared to
non-operated animals at 13 weeks of age, and the difference in glucose level was statistically significant
(Mann-Whitney U-test, p = 0.016)).
More significant differences came from serum analysis in male MKR group. None of the operated
male MKR mice developed dysplasia. Mann Whitney U-test performed between 43 weeks old
non-operated and operated mice that developed neoplasia showed decreased glucose, C-peptide and
leptin levels (Table 4). As expected, in mice that developed cancer IL-6 serum levels were higher
compared to non-operated group (Table 4). Non-operated MKR males at 43 weeks of age had higher
levels C-peptide compared to non-operated MKR males at 13 weeks of age (Mann-Whitney U-test,
p = 0.010). Furthermore, Mann-Whitney U-test showed significant differences in insulin levels between
non-operated MKR females and MKR males at 43 weeks of age (p = 0.008).
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Table 3. Serum metabolic parameters in operated WT mice. Data were expressed as Median (Q1; Q3).
Data obtained in operated mice affected by dysplasia or cancer were compared to strain-, sex-,
and age-matched non-operated animals (43 weeks). K–W test indicates the Kruskal-Wallis test result
used for multiple comparisons among the three groups of mice. A p-value lower than 0.05 was
considered statistically significant.
WT
Females
Non-Operated
n = 8
Dysplasia
n = 13
Cancer
n = 6
K–W
Test
Glucose
(mg/dL)
177.5
(147.3; 192.3)
196.0
(125.0; 254.0)
235.5
(225.3; 291.5) 0.179
Insulin
(pg/mL)
423.4
(374.2; 462.2)
376.5
(360.0; 390.0)
443.5
(420.0; 741.8) 0.215
C-Peptide
(pg/mL)
323.0
(295.2; 423.9)
313.3
(240.1; 405.8)
439.0
(346.9; 522.5) 0.334
Leptin
(pg/mL)
2345.8
(1998.7; 2912.6)
1928.0
(1515.7; 2540.0)
1784.5
(1640.1; 1962.0) 0.103
IL-6
(pg/mL)
23.2
(3.1; 31.9)
29.0
(1.4; 55.2)
59.8
(21.8; 74.3) 0.292
WT
Males
Non-Operated
n = 8
Dysplasia
n = 11
Cancer
n = 6
K–W
Test
Glucose
(mg/dL)
191.0
(166.3; 208.3)
209.0
(175.3; 252.8)
222.0
(157.3; 242.5) 0.469
Insulin
(pg/mL)
838.7
(689.6; 860.4)
784.0
(467.5; 973.1)
1406.4
(1033.8; 1912.6) 0.094
C-Peptide
(pg/mL)
761.7
(407.5; 922.5)
661.2
(334.9; 755.4)
850.2
(814.3; 1060.2) 0.210
Leptin
(pg/mL)
4902.2
(3801.4; 6749.4)
1564.8
(1336.5; 2811.2)
1104.1
(894.0; 1415.5) 0.011
IL-6
(pg/mL)
24.9
(13.4; 28.3)
29.0
(11.1; 40.7)
65.8
(37.4; 162.7) 0.121
In the end, we analyzed the trend of each serum parameter across the four groups and on the basis
of histology. Across non-operated groups we found significant insulin (Cuzick z = +5.16, p < 1·10−4)
and C-peptide increased levels (Cuzick z = +5.04, p < 1 × 10−4) and leptin decreased level (Cuzick
z = −3.34, p = 8 × 10−4). No significant differences in glucose and IL-6 levels were found. The analysis
of the trend across mice that developed dysplasia was performed across three group (MKR males
did not develop dysplasia) and showed, in parallel with the healthy mice, increased insulin (Cuzick
z = +3.51, p = 4 × 10−4) and C-peptide serum levels (Cuzick z = +3.28, p = 0.001). No differences on the
other parameters were found. Serum analysis of mice that developed cancer showed, in parallel with
the others, increased insulin (z = +5.06, p < 1 × 10−4) and C-peptide levels (z = +4.42, p < 1 × 10−4)
and decreased glucose and leptin levels (z = −2.89, p = 0.004 and z = −2.99, p = 0.003, respectively).
IL-6 levels were comparable (z = +0.88, p = 0.380).
2.7. Insulin Signaling in Operated Mice Esophageal Tissue
To evaluate the involvement of insulin and IGF receptors in the oncogenic process during
esophageal cancer onset related to duodeno-esophageal chronic reflux condition, insulin signaling
on the esophageal tissue of operated animals was analyzed. Also in this case, the control groups
included strain-, age-, and sex-matched, non-operated animals. Analysis of the esophageal tissue of
WT females (Figure 2) showed a significantly higher phosphorylation level of IGF1R in both dysplastic
(7-fold higher) and cancer (2.2-fold higher) tissues compared to healthy tissue. IGF1R hyperactivation
could lead to the increase in ERK1/2 protein phosphorylation (10-fold and 2.6-fold in dysplastic
and cancer tissue, respectively), compared with basal state (Figure 2B). Total IGF1R expression was
up-regulated in cancer tissue compared to healthy tissue. Moreover, activation of p70S6K was found
in dysplastic tissue, as well as an increase in IRS1 total protein degradation. Tissue from WT males
Int. J. Mol. Sci. 2018, 19, 1198 8 of 22
(Figure 3) showed a higher phosphorylation state of both IR and IGF1R in cancer tissue compared with
healthy non-operated esophageal tissue (Figure 3B). Cuzick’s trend test showed that phosphorylation
increased in parallel with disease progression (z = +3.13, p = 0.002 for IR phosphorylation and z = +4.16,
p < 1 × 10−5 for IGF1R phosphorylation, respectively). In parallel, increased ERK1/2 phosphorylation
levels were found in both dysplastic and cancer tissues compared with control tissues. Total IR
expression level in cancer tissues from WT males was decreased compared with healthy tissue
(Figure 3A). The data were confirmed by the Cuzick’s trend test result, which showed a significant
decrease in IR expression along with disease progression (z = −2.26, p = 0.024). As expected, increased
Akt phosphorylation levels were found in cancer tissue. Unlike in WT females, higher levels of p70S6K
were found in both dysplastic and neoplastic lesions in WT males. Cuzick’s trend test showed an
increase of p70S6K expression along with disease progression (z = +2.85, p = 0.004).
Table 4. Serum metabolic parameters in operated MKR mice. Data were expressed as Median
(Q1; Q3). Data obtained in operated mice affected by dysplasia or cancer were compared to strain-, sex-,
and age-matched non-operated animals (43 weeks). K–W test indicates the Kruskal-Wallis test result
used for multiple comparisons among the three groups of mice. M–W test indicates Mann-Whitney
U-test result used to compare data distribution between two groups of mice (No MKR males were
affected by dysplastic lesions). A p-value lower than 0.05 was considered statistically significant.
MKR
Females
Non-Operated
n = 8
Dysplasia
n = 4
Cancer
n = 10
K–W
Test
Glucose
(mg/dL)
188.0
(169.0; 206.8)
258.0
(220.3; 302.0)
219.5
(201.3; 241.3) 0.102
Insulin
(pg/mL)
2713.9
(2266.0; 5179.1)
4884.8
(4595.4; 5084.0)
3160.0
(2160.8; 3517.8) 0.055
C-Peptide
(pg/mL)
1498.9
(1182.9;1729.7)
1711.2
(1496.1;1926.5)
1534.4
(1074.7;2560.9) 0.919
Leptin
(pg/mL)
1548.9
(968.1;1975.2)
1323.0
(910.8;1565.1)
921.1
(842.0;1123.9) 0.192
IL-6
(pg/mL)
20.5
(14.3;29.6)
28.7
(17.2;36.8)
40.5
(11.2;57.8) 0.390
MKR
Males
Non-Operated
n = 8
Cancer
n = 16
M–W
Test
Glucose
(mg/dL)
207.5
(189.3; 237.0)
171.0
(151.3; 199.5) 0.037
Insulin
(pg/mL)
10780.8
(8810.5;
12018.1)
8043.4
(5268.8;
10373.4)
0.126
C-Peptide
(pg/mL)
5238.0
(4263.1; 5635.3)
2168.2
(1383.7; 3413.6) 0.043
Leptin
(pg/mL)
1344.1
(1182.7; 1524.9)
808.2
(640.4; 1077.6) 0.014
IL-6
(pg/mL)
17.7
(12.1; 23.6)
73.6
(54.8; 152.7) 0.009
Esophageal tissue analysis from MKR females showed statistically significant differences in most
of the proteins analyzed (Figure 4). IR, IGF1R and IRS1 total protein expression decreased along with
disease progression, as confirmed by Cuzick’s test for trend (z = −3.07, p = 0.002; z = −2.74, p = 0.006
and z = −3.71, p < 1 × 10−5, for IR, IGF1R and IRS1, respectively) (Figure 4A). On the other hand,
the relative phosphorylation levels of both IR and IGF1R significantly increased along with disease
progression (z = +2.92, p = 0.004 for phospho-IR; z = +3.21, p = 0.001 for phospho-IGF1R) (Figure 4B).
Akt total protein expression was higher in dysplastic and neoplastic lesions although the differences
did not reach statistical significance. Similarly, p70S6K total protein expression increased in both
dysplastic and neoplastic tissues but the trend did not reach statistical significance (z = +1.64, p = 0.108).
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On the contrary, the phosphorylation state of p70S6K was decreased along with disease progression
(z = −2.32, p = 0.020). ERK1/2 phosphorylation level was higher in cancer tissues compared with
healthy esophagus. Cuzick’s trend test showed that phospho-ERK1/2 expression increased along
with disease progression (z = +3.10, p = 0.002). ERK1/2 total expression was higher in cancer tissue
compared to control tissue and the differences were close to statistical relevance (M–W, p = 0.021).
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Figure 2. Insulin signaling in operated WT female mice esophageal tissue. Data are represented as
Median (Q1; Q3). Data obtained in operated mice affected by dysplasia or cancer were compared to
strain-, sex-, and age-matched, non-operated animals (43 weeks). K-W indicates the Kruskal-Wallis test
result, used for multiple comparisons among the three groups of mice. The Mann-Whitney U-test was
performed to compare data distribution between two groups of mice. After correction a A p-value lower
than 0.016 (Bonferroni adjustment) was considered statistically significant: * p < 0.016; ** p < 1.6× 10−3.
(A) Total protein expression: the quantity of each total protein considered was expressed in ng/100 mg
of total protein extracted by the distal mice esophageal segment. (B) Phosphorylated protein expression:
the amount of the six phospho-proteins considered was expressed as phosphorylated Units for each ng
of the corresponding total protein amount. Proteins were quantified by Luminex-xMAP Technology on
the basis of a standard curve. Beta-tubulin expression was used as the internal loading control.
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Figure 3. Insulin signaling in operated WT male mice esophageal tissue. Data are represented as
Median (Q1; Q3). Data obtained in operated mice affected by dysplasia or cancer were compared to
strain-, sex-, and age-matched, non-operated animals (43 weeks). K-W indicates the Kruskal-Wallis
test result, used for multiple comparisons among the three groups of mice. The Mann-Whitney U-test
was performed to compare data distribution between two groups of mice. A p-value lower than 0.016
(Bonferroni adjustment) was considered statistically significant: * p < 0.016; ** p < 1.6 × 10−3. (A) Total
protein expression: the quantity of each total protein considered was expressed in ng/100 mg of
total protein extracted by the distal mice esophageal segment. (B) Phosphorylated protein expression:
the amount of the six phospho-proteins considered was expressed as phosphorylated Units for each ng
of the corresponding total protein amount. Proteins were quantified by Luminex-xMAP Technology on
the basis of a standard curve. Beta-tubulin expression was used as the internal loading control.
Analogous to MKR females, protein expression in esophageal tissue from MKR males showed
a significant decrease of both IR and IGF1R expression in cancer compared with control tissue
(Figure 5A). Also in this group, IGF1R phosphorylation was increased in cancer tissue (Figure 5B).
The p70S6K expression was increased, as well as IRS1 phosphorylation and degradation. Surprisingly,
the phosphorylation of AkT protein was significantly reduced in cancer tissue. Mitogenic pathway
activation was found to be higher in cancer, with a phosphorylation level of ERK1/2 15-fold higher in
cancer than control tissue.
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Figure 4. Insulin signaling in operated MKR female mice esophageal tissue. Data are represented as
Median (Q1; Q3). Data obtained in operated mice affected by dysplasia or cancer were compared to
strain-, sex-, and age-matched, non-operated animals (43 weeks). K-W indicates the Kruskal-Wallis
test result, used for multiple comparisons among the three groups of mice. Mann-Whitney U-test
was performed to compare data distribution between two groups of mice. A p-value lower than 0.016
(Bonferroni adjustment) was considered statistically significant: * p < 0.016; ** p < 1.6 × 10−3. (A) Total
protein expression: the quantity of each total protein considered was expressed in ng/100 mg of
total protein extracted by the distal mice esophageal segment. (B) Phosphorylated protein expression:
the amount of the six phospho-proteins considered was expressed as phosphorylated Units for each ng
of the corresponding total protein amount. Proteins were quantified by Luminex-xMAP Technology on
the basis of a standard curve. Beta-tubulin expression was used as the internal loading control.
At the end, we analyzed the trend of each protein amount across the four groups and on the
basis of histology. Across non-operated groups we found a significant up-regulation of IR (Cuzick
z = +4.92, p < 1·10−4), IGF1R (Cuzick z = +5.01, p < 1 × 10−4), and ERK1/2 (Cuzick z = +3.08, p = 0.002)
total protein expression. Phospho-p70S6K expression was increased across the four groups (Cuzick
z = +3.44, p = 6 × 10−4), and in parallel, relative phospho-IGF1R expression was decreased (Cuzick
z = −4.19, p < 1 × 10−4).
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Figure 5. Insulin signaling in operated MKR male mice esophageal tissue. Data are represented as
Median (Q1; Q3). Data obtained in operated mice affected by cancer were compared to strain-, sex-,
and age-matched, non-operated animals (43 weeks). The Mann-Whitney U-test was performed to
compare data distribution between the two groups of mice. A p-value lower than 0.05 was considered
statistically significant: * p < 0.05; ** p < 0.005. (A) Total protein expression: the quantity of each
total protein considered was expressed in ng/100 mg of total protein extracted by the distal mice
esophageal segment. (B) Phosphorylated protein expression: the amount of the six phospho-proteins
considered was expressed as phosphorylated Units for each ng of the corresponding total protein
amount. Proteins were quantified by Luminex-xMAP Technology on the basis of a standard curve.
Beta-tubulin expression was used as the internal loading control.
Comparing protein expression on dysplastic tissues, the increase of IGF1R total protein expression
and the decrease of relative phospho-IGF1R level were confirmed by the trend test (Cuzick z = +3.45,
p = 6 × 10−4 for IGF1R; z = −3.71, p = 2 × 10−4 for phospho-protein). When we evaluated protein
expression on cancer tissues, the data confirmed the same trend (Cuzick z = +3.05, p = 0.002 for IGF1R
and z = −3.60, p = 3 × 10−4 for phospho-protein) and also showed an increased expression of total
ERK1/2 (Cuzick z = +3.04, p = 0.002) across the groups.
2.8. Ki-67 Nuclear Protein Expression on Esophageal Lesions
To evaluate whether IGF1R increased expression was related to cellular proliferation pathway
induction, Ki-67 nuclear protein expression was analyzed on esophageal tissue specimens.
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As showed in Figure 6, in dysplastic lesions the average number of Ki-67 positive cells was 17.5
(±3.5) and 25.5 (±2.7) in WT and MKR tissues, respectively, while 1.5 (±0.8) and 26.4 (±5.4) positive
cells were found in WT and MKR neoplastic lesions, respectively.
Figure 6. Representative case of Ki-67 nuclear protein expression on healthy, dysplastic and neoplastic
esophageal tissues in WT and MKR mice. Non-operated mice (healthy tissue): WT male and MKR
male at 43 weeks of age. Dysplasia: squamous high-grade dysplastic lesions (HGD) in WT female
and MKR female. Cancer: Moderately well differentiated ESCC in WT male and MKR male. Original
magnification 40×.
2.9. HER-2 Expression in Cancer Progression
On the basis of our previous retrospective study [18], we hypothesized the involvement of other
growth factor receptors and their cooperation with the insulin/insulin-like growth factor-1 axis in the
evolution of these tumors. HER2 overexpression plays a critical role in the development, progression
and metastasis of many malignancies such as breast cancer [12,13,19], gastric cancer [20,21] and
esophageal cancer [18,22]. To evaluate whether in our carcinogenesis model (related exclusively to
duodenal content chronic reflux) that HER2 could play a role, HER2 total protein expression was
evaluated in esophageal tissue on both non-operated and operated mice.
Immunohistochemistry staining of FFPE esophageal tissues showed HER2 positivity in both
dysplastic and neoplastic lesions in ESCC and EASC, in WT and MKR mice, as previously described in
human specimens [18,22,23]. As shown in the representative images (Figure 7A) all dysplastic and
neoplastic lesions showed HER2 positivity. Data were confirmed also by Western blotting analysis
(Figure 7B). Densitometric analysis (Figure 7C) showed a higher HER2 expression in neoplastic
lesions compared to dysplastic lesions of both WT and MKR mice. Furthermore, in ESCC tissue from
MKR mice, HER2 expression was significantly higher (30% more) that in ESCC WT tissue.
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Figure 7. Representative case of HER2 overexpression detected by Immunohistochemistry IHC (A) and
Western blotting (B). (A) WT (wild-type mouse esophageal tissue). From left to right: 1. Non-operated
(healthy tissue) WT female at 43 weeks of age (IHC negative; original magnification 100×). 2. Squamous
Dysplasia (LGD/HGD) in WT male (IHC2+; original magnification 200×). 3. ESCC in WT male (IHC3+
on both dysplastic and infiltrative component; original magnification 200×). 4. EASC in WT male
(IHC2+ in squamous component and IHC1+ in glandular component; original magnification 200×).
MKR (MKR mouse esophageal tissue). From left to right: 1. Non-operated (healthy tissue) MKR
female at 43 weeks of age (IHC negative; original magnification 100×). 2. Squamous Dysplasia (HGD)
in MKR female (IHC3+; original magnification 200×). 3. ESCC in MKR female (IHC2+; original
magnification 200×). 4. EASC in MKR male (IHC3+ in both squamous and glandular component;
original magnification 200×). (B) Thirty micrograms of extracted total proteins were separated in
SDS-PAGE and transferred to nitrocellulose membranes. Membranes were blotted with anti-HER2
(molecular weight = 185 KDa) and anti-β-actin (molecular weight = 42 KDa) antibodies. Non-operated
(healthy tissue) WT and MKR male at 43 weeks of age. Dysplasia: squamous HGD dysplasia in WT
and MKR female. ESCC in WT and MKR female. EASC in WT and MKR male. (C) The densitometric
intensity of bands is shown in the bar graphs. Data are presented as the mean ± SEM and the relative
protein expression is indicated as n-fold of protein amount detected on WT dysplastic tissue which
was set equal to 1 arbitrary unit. * p < 0.05; ** p < 0.01.
3. Discussion
Esophageal cancer is the sixth most common cause of cancer-related mortality in the world [24].
This malignancy exists in two main forms with distinct etiological and pathological characteristics,
esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) [25].
It is widely accepted that ESCC is associated with smoking and alcohol consumption [26]. EAC is
the most common histological subtype of esophageal cancer in the west [27]. Barrett’s esophagus
(BE) is the only known precursor for EAC and develops in patients with gastroesophageal reflux
disease [28,29]. It is reported that not only gastric acid, but also the reflux of duodenal content plays
an important role in the generation of Barrett’s metaplasia and EAC [30].
Previous studies have demonstrated that refluxed duodenal contents cause esophageal carcinoma
in rats without exposure to carcinogens [31–33]. The histological spectrum of these carcinomas
includes ESCC, EAC and adenosquamous carcinoma [25].
With the total exclusion of the stomach, our mouse surgical model showed that refluxed duodenal
content caused esophageal cancer without exposure to carcinogens, and without any prevalence
between the two tumor histological types (47.4% were ESCC and 52.6% were EASC). It is unclear what
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factors lead to the formation of carcinomas of specified histology, but in our model, adenosquamous
carcinoma seems to be related to male gender.
The first important result that came from this work is that the hyperinsulinemic condition in MKR
mice increases more than six-fold the risk of developing neoplastic esophageal lesions in the presence
of duodenal chronic reflux.
The metabolic status analysis of the mice before surgery showed, as expected, that MKR mice have
higher serum insulin and C-peptide levels compared to age- and sex-matched WT mice. Body weight
was sensibly lower in MKR mice compared to the WT counterpart which tended to accumulate more
adipose tissue than MKR mice, as confirmed by leptin serum level measurements. Both young and
older WT males accumulated more adipose tissue and had higher insulin levels than females WT
counterparts. Differences in insulin levels between MKR males and females were especially evident
in older age (43 weeks). The highest insulin secretion in MKR male mice suggested that males were
affected by a more severe insulin-resistance that could evolve towards an overt diabetes. These
gender-specific differences may be attributed to estrogens, which exert a protective effect on pancreatic
β-cells [34]. Moreover, it is known that male sex is a risk factor for the onset of this type of cancer
and our results confirmed this epidemiological data. On the basis of insulin and C-peptide serum
levels, the four groups of animals were ordered lowest to highest as follows: WT females, WT males,
MKR females and MKR males.
Insulin and insulin-like growth factor 1 are closely related hormones that control different aspects
of growth and metabolism in many organisms [35–37]. At physiological levels, insulin and IGF-1
fully activate their cognate receptors, IGF-1 can also activate IR/IGF1R hybrid receptors, and at
supraphysiological levels they can also bind and activate the other receptor in cell culture models,
although with reduced affinity [38]. Today it is known that IGF1R is involved in mitogenesis,
transformation and protection from apoptosis [39,40]. A pivotal role of IGF1R signaling in esophageal
cancer onset in our animal model was first suggested by the high activation level of the IGF1R in
dysplastic and cancer tissues of WT normoinsulinemic mice, suggesting that IGF1R is involved in
duodenal reflux-dependent esophageal carcinogenesis even in the absence of hyperinsulinemia.
The hyperinsulinemic condition of MKR mice is responsible for an important alteration of the
expression and activation of IR/IGF1R also in esophageal tissue which is not a classical target tissue
of insulin action, as demonstrated by the data from MKR non-operated animals. Our data showed
that hyperinsulinemia was responsible for an increase in both metabolic and mitogenic insulin signal
transduction as confirmed by the significant increase in Akt phosphorylation level, higher inhibitory
IRS1 phosphorylation (as an attempt to switch-off an over-activated insulin signal) and an increase
in ERK1/2 expression. These molecular alterations were increased across the four ordered groups.
This evidence might explain the differences in tumor incidence observed between females (WT = 30.0%,
MKR = 55.5%,) and males (WT = 33.3%, MKR = 94.4%) in both groups. The IGF1R over-expression was
observed in all cases, healthy, dysplastic and cancer tissue compared to WT tissue. The over-expression
in dysplasia and cancer was related to cellular proliferation pathway induction increase in MKR
lesions. Importantly, cancer tissue analysis showed a very small amount of insulin and IGF1 receptors
compared to non-operated or dyplastic tissue or both in all groups of animals, with the exception of
WT females. Our study is not unique in finding lower growth factor receptor expression levels in
tumor tissue; in breast and colorectal cancer; this phenomenon has also been described and it seems to
be related to the advanced and poorly differentiated carcinoma [41,42]. We showed similar results in
esophageal adenocarcinoma tissue from patients analyzed in our retrospective study published last
year [18]. In the present study, we showed an important activation of p-ERK1/2 in both dysplastic and
cancer MKR esophageal tissue, which is known to be a mitogenic signaling protein down-stream of
IGF1R activation. In an attempt to clarify IGF1R regulation in duodenal reflux-induced esophageal
carcinogenesis we hypothesized a receptor cross-talk between IGF1R and another crucial growth
factor receptor that is known to have a pivotal role in EAC carcinogenesis and disease progression,
such as Human Epithermal Growth Factor receptor 2, HER2. Our group together with other studies
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showed HER2 over-expression on human Barrett’s tissue and esophageal adenocarcinoma [18,22,43].
In our previous study [18] in vitro experiments on OE19 human esophageal adenocarcinoma cell
line were performed. HER2 expression and phosphorylation levels resulted to be significantly
up-regulated after insulin treatment. In the same set of experiments, insulin-induced cell proliferation
was inhibited by Trastuzumab, a humanized monoclonal antibody against HER2 receptor successfully
used in early-stage and metastatic breast cancer therapy of patients with HER2-overexpressing tumors,
suggesting a cross-talk between insulin and HER2 signals. Here, our hypothesis could be supported
by immunohistochemical and biochemical analyses confirming that both, dysplastic and cancer tissues
over-expressed HER2. Moreover, the hyperinsulinemic condition increased HER2 cancer expression.
A cross talk between the ErbB/HER family and IGF1R signaling pathway has been proven in breast
cancer [11–13] and the evidences reported in this study supports the hypothesis that this mechanism
could be also involved in this context.
4. Materials and Methods
4.1. Animals
Procedures involving animals and their care were conducted according to Italian law on the use
of experimental animals (DL n. 116/92 art. 5). This study was approved by the Ethical Committee of
University of Padova (Comitato Etico di Ateneo sulla Sperimentazione Animale, Protocol n. 32140,
Project n. 40/2011, approved on June 14, 2011). All animals were housed and maintained in an animal
facility at the Veneto Institute of Oncology (Istituto Oncologico Veneto-IOV-IRCCS). Mice were kept
on a 12-h light/dark cycle with access to a standard laboratory chow diet and fresh water ad libitum.
All the mice used in this study were on the FVB/N background, wild-type (WT) and transgenic,
hyperinsulinemic, insulin-resistant MKR+/+ (MKR) mice.
4.2. Surgical Procedure
At 13 weeks of age, 39 WT (n = 20 females, n = 19 males) and 40 MKR (n = 20 females,
n = 20 males) mice underwent jejunum-esophageal anastomosis. The operation to induce chronic
duodeno-esophageal reflux was performed according to the microsurgical procedure described in
our previous studies [43,44] with some modification. Briefly, following induction of anesthesia
with intraperitoneal injection (tiletamine/zolazepam (25 mg/Kg) and xylazine (2 mg/Kg)), a 2-cm
midline laparotomy incision was made. The stomach was completely closed with a ligature; a loop of
jejunum, 2 cm distal to the ligament of Treitz, was anastomozed side-to end to the esophago-gastric
junction, leaving the stomach in situ. Postoperatively, the animals had free access to water and food.
Thirteen-week-old and 43-week-old non-operated WT (n = 8, for each gender and for each age) and
MKR (n = 8, for each gender and for each age) were used as control mice.
4.3. Tissues Collection
Thirty weeks after surgery, blood samples were recovered through intracardiac aspiration on
2-hr fasted mice. After euthanasia, the entire esophagus was removed and opened longitudinally to
examine macroscopic morphological changes. The tissue was divided longitudinally: one portion
was fixed in 4% buffered formalin and embedded in paraffin for histological and immunohistological
assessment, and the remaining longitudinal strip was divided into the three esophageal segments
(proximal, medial and distal), frozen in liquid nitrogen and it was stored at −80 ◦C for subsequent
protein expression analysis.
4.4. Histological and Immunohistochemical Analysis
FFPE (Formalin-Fixed, Paraffin-Embedded) samples were cut serially (4 µm thick) and stained
with haematoxylin and eosin. Two experienced gastrointestinal pathologists (Cinzia Giacometti, Matteo
Fassan) reviewed all the slides in a blinded fashion. On the FFPE samples, immunohistochemical
Int. J. Mol. Sci. 2018, 19, 1198 17 of 22
analysis for HER2 was performed with the Oracle HER2 Bond IHC system (CB11) mouse monoclonal
antibody (Menarini Diagnostics, Florence, Italy), whilst immunohistochemical analysis for Ki-67
was performed with anti-Ki-67 monoclonal antibody (clone SP6) (Spring Bioscience Corporation,
Pleasanton, CA, USA) using the automated Leica Microsystems Bond-Max (Leica, Wetzlar, Germany).
The number of immunoreactive Ki-67 cells was determined as the average of the positive
immunostained cells in five fields (magnification 40×) selected randomly on three slides for each
tissue sample.
4.5. Serum Analysis
Blood glucose (mg/dL) was determined on fresh blood samples with a glucometer (Abbott
Laboratories®, Irving, TX, USA). Serum was extracted and frozen in liquid nitrogen. Insulin (pg/mL),
C-peptide (pg/mL), leptin (pg/mL) and IL-6 (pg/mL) levels were simultaneously measured in each
serum sample with Luminex® xMAP® Technology (Merck KGaA, Darmstadt, Germany). Each measure
was performed in duplicate. Serum analyte quantitative analyses were performed with Luminex x
PONENT 3.1 Software (Luminex Corporation, Austin, TX, USA) using a Five Parameter Logistic
curve fitting.
4.6. Esophageal Tissue Analysis
Total proteins were obtained from fresh frozen distal esophageal segments. After mechanical lysis
tissue fragments were treated with NP40 Lysis Buffer added with protease and phosphatase inhibitors
(Thermo Scientific Pierce, Rockford, IL, USA). Bicinchoninic acid (BCA) assay (Thermo Scientific Pierce,
Rockford, IL, USA) was performed to quantify extracted total proteins. For each sample, 20 µg of total
proteins were analyzed. Signaling pathways for IR/ IGF1R were determined using Luminex xMAP®
technology. Each measure was performed in duplicate.
4.7. Immunoblotting
Thirty µg of extracted total proteins were separated in SDS-PAGE and transferred to nitrocellulose
membranes. After being blocked with TBS-T (150 mM NaCl, 50 mM Tris-HCl pH 7.4, 0.1% Tween-20)
supplemented with 5% BSA (Bovine Serum Albumin), membranes were blotted with anti-HER2
monoclonal antibody (clone D8F12) (Cell Signaling Technology, Danvers, MA, USA). Moreover,
membranes were blotted with an anti-β-actin polyclonal antibody (Sigma–Aldrich, St. Louis, MO, USA)
used as a control for equal loading. Images were acquired and digitally scored with a densitometer
image analyzer (Quantity one software, Bio-Rad, Hercules, CA, USA). Four independent samples were
analyzed for each group of non-operated animals. Densitometric analysis was performed normalizing
protein expression to β-actin expression. Data were presented as the mean± SEM (Standard Error of
the Mean). Data on dysplastic tissue represented the mean of n = 6 and n = 4 independent samples
from WT and MKR mice, respectively. Data on ESCC tissue represented the mean of n = 5 and n = 6
independent samples from WT and MKR mice, respectively. Data on EASC tissue represented the mean
of six independent samples for each group of animals. Relative protein expression was represented as
n-fold of protein amount detected on WT dysplastic tissue which was set equal to 1 arbitrary unit.
4.8. Statistical Analysis
Fisher’s exact test was used for comparison of categorical variables. The Kruskal-Wallis test was
used for multiple comparisons. A p-value lower than 0.05 was considered statistically significant.
The Mann-Whitney U-test, followed by Bonferroni correction, was used to assess differences between
two groups of mice. In the case of multiple comparisons among four groups, following Bonferroni
correction, the p value was adjusted at 0.008. In the case of multiple comparison among three groups,
the Bonferroni-adjusted p value was 0.016. On the basis of insulin secretion, mice groups were
expressed as an ordered categorical variable. Cuzick’s test for trend was used to evaluate the trend of
protein expression across the four ordered groups: WT females, WT males, MKR females, MKR males.
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Cuzick’s test for trend was also used to evaluate protein expression along with disease severity
progression: non-operated (healthy tissue), dysplastic, and neoplastic lesions.
The amount of the specific total proteins from esophageal tissue was calculated on the basis of a
standard curve with known concentration. Beta-tubulin amount was used as internal loading control.
Protein was expressed as ng per 100 µg of total protein loaded. Phosphorylated protein expression
was evaluated as a ratio between the phosphorylated protein amount/ng of total corresponding protein.
Beta-tubulin amount was used as an internal loading control.
Data were expressed as a median and interquartile range (Q1; Q3). Only the data referred to in
the densitometric analysis of immunoblotting were expressed as mean ± SEM, and in this case the
Student’s t test was used to assess differences between groups. A p-value lower than 0.05 was assumed
to indicate a significant difference. Data analyses were performed with SPSS v20 and Stats-Direct.
5. Conclusions
In conclusion, the reflux of duodenal contents has a great potential for malignant initiation,
inducing not only EASC but also ESCC. IGF1R activation seems to play a crucial role in esophageal
carcinogenesis in this animal model. Hyperinsulinemia significantly increases reflux-related
esophageal cancer incidence, possibly through enhancing IGF1R/p-ERK1/2 pro-proliferation signaling
in esophageal cells. Because of the pivotal role of HER2 in esophageal carcinogenesis and the possibility
of heterodimers formation between IGF1R and HER2, we suggest that a cross talk between the
ErbB/HER family and IGF1R signaling pathway could sustain IGF1R activation and down-stream
p-ERK1/2 mediated proliferation, in particular in hyperinsulinemic MKR mice in which IGF1R is
highly expressed even in absence of lesions, and in which the higher insulin concentration induces
cancer cell HER2 over-expression (Figure 8).
Figure 8. Hypothesized hyperinsulinemia-induced cancerogenetic mechanisms. Insulin and
insulin-like growth factor 1 are closely related hormones that control different aspects of growth
and metabolism in many organisms. At physiological levels, insulin and IGF-1 fully activate their
cognate receptors and IGF-1 can also activate IR/IGF1R hybrid receptors. At supraphysiological levels
they can also bind and activate each other’s’ receptor in cell culture models, although with reduced
affinity. Activated IR/IGF1R receptors phosphorylate target proteins such as Insulin Receptor Substrate
(IRSs) proteins on selective tyrosine residues (Tyr) that serve as docking sites for downstream effector
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molecules. Phosphorylated IRS1 activates the metabolic PI3K/Akt pathway. Activated Akt regulates
glucose metabolism and induces the mitogenic (ERK/MAPK) pathway involved in carcinogenic
mechanism. Serine (Ser)/Threonine phosphorylation of the IRS proteins is a key negative-feedback
control mechanism that uncouples the IRS proteins from their upstream and downstream effectors and
terminates signal transduction in response to insulin, under physiological conditions. Analogous
mechanisms are involved in the molecular pathophysiology of insulin resistance by activating
serine/threonine IRS kinases (such as the p70S6K) that phosphorylate the IRS proteins and inhibit their
function. Hyperinsulinemia is responsible of receptors hyperactivation inducing IR, IGF1R, and ERK
over-expression. HER2 signal activation is known to have a pivotal role in esophageal cancerogenesis
and disease progression. Hyperinsulinemia is able to induce also HER2 overexpression. HER2 is
the preferential dimerization partner of other members of the ErbB family and other growth factor
receptors. A cross-talk between HER2 and IGF1R signaling pathway has been proven in breast cancer
through an heterodimerization mechanism. An analogous mechanism is proposed also in this context,
in which hyperinsulinemia-induced IGF1R overexpression might enhance the possibility to form
HER2/IGF1R heterodimers, promoting mitogenic pathway activation and, in turn, cancer.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/4/
1198/s1.
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Abbreviations
EAC Esophageal Adenocarcinoma
ERK Extracellular signal-Regulated Kinase
ESCC Esophageal Squamous Cell Carcinoma
GERD Gastro-Esophageal Reflux Disease
HER2 Human Epidermal growth factor receptor 2
IGF1R Insulin-like growth factor 1 receptor
IL-6 Interleukin 6
IR Insulin receptor
MAPK Mitogen-Activated Protein Kinase
pS Phosphorylated serine residue
pY Phosphorylated tyrosine residue
Thr Threonine residue
Tyr Tyrosine residue
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